Download PDF
Semin Thromb Hemost 2008; 34(5): 439-444
DOI: 10.1055/s-0028-1092873
© Thieme Medical Publishers

Prohemostatic Agents to Prevent Perioperative Blood Loss

Jerrold H. Levy1 , Kenichi A. Tanaka1
  • 1Emory University Hospital, Atlanta, Georgia
Further Information

Publication History

Publication Date:
27 October 2008 (online)

    Permissions and Reprints

ABSTRACT

Surgical patients represent a unique group of patients where therapeutic approaches can be preemptively administered. Pharmacologic strategies to prevent or decrease perioperative bleeding function to attenuate inflammatory responses, reduce hemostatic activation, or provide prohemostatic effects to reduce bleeding and the need for allogeneic transfusions. This article will discuss pharmacologic prohemostatic agents (antifibrinolytics, protamine, desmopressin, fibrinogen, purified protein concentrates, recombinant factor VIIa).

KEYWORDS

Aprotinin - aintifibrinolytics - bleeding - desmopressin - fibrinogen - factor VIIa - recombinant - transfusion - surgery

REFERENCES

  • 1 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356 2301-2311
    CrossrefPubMedGoogle Scholar
  • 2 Spiess B D, Royston D, Levy J H et al.. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes.  Transfusion. 2004;  44 1143-1148
    CrossrefPubMedGoogle Scholar
  • 3 Spiess B D. Risks of transfusion: outcome focus.  Transfusion. 2004;  44 4S-14S
    CrossrefPubMedGoogle Scholar
  • 4 Spiess B D. Transfusion of blood products affects outcome in cardiac surgery.  Semin Cardiothorac Vasc Anesth. 2004;  8 267-281
    CrossrefPubMedGoogle Scholar
  • 5 Levy J H. Massive transfusion coagulopathy.  Semin Hematol. 2006;  43 S59-S63
    CrossrefPubMedGoogle Scholar
  • 6 Karkouti K, Wijeysundera D N, Yau T M et al.. The independent association of massive blood loss with mortality in cardiac surgery.  Transfusion. 2004;  44 1453-1462
    CrossrefPubMedGoogle Scholar
  • 7 Despotis G J, Zhang L, Lublin D M. Transfusion risks and transfusion-related pro-inflammatory responses.  Hematol Oncol Clin North Am. 2007;  21 147-161
    CrossrefPubMedGoogle Scholar
  • 8 Levy J H, Tanaka K A, Steiner M E. Evaluation and management of bleeding during cardiac surgery.  Curr Hematol Rep. 2005;  4 368-372
    PubMedGoogle Scholar
  • 9 Levy J H. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.  Am J Health Syst Pharm. 2005;  62 S15-S19
    CrossrefPubMedGoogle Scholar
  • 10 Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients.  Expert Opin Drug Saf. 2006;  5 539-552
    CrossrefPubMedGoogle Scholar
  • 11 Levi M, Cromheecke M E, de Jonge E et al.. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.  Lancet. 1999;  354 1940-1947
    CrossrefPubMedGoogle Scholar
  • 12 Henry D A, Moxey A J, Carless P A et al.. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.  Cochrane Database Syst Rev. 2001;  CD001886
    PubMedGoogle Scholar
  • 13 Sedrakyan A, Treasure T, Elefteriades J A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.  J Thorac Cardiovasc Surg. 2004;  128 442-448
    CrossrefPubMedGoogle Scholar
  • 14 Mangano D T, Tudor I C, Dietzel C. The risk associated with aprotinin in cardiac surgery.  N Engl J Med. 2006;  354 353-365
    CrossrefPubMedGoogle Scholar
  • 15 Mangano D T, Miao Y, Vuylsteke A et al.. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.  JAMA. 2007;  297 471-479
    CrossrefPubMedGoogle Scholar
  • 16 Fergusson D A, Hébert P C, Mazer C D et al.. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.  N Engl J Med. 2008;  358 2319-2331
    CrossrefPubMedGoogle Scholar
  • 17 Levi M M, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy.  Int J Hematol. 2002;  76(Suppl 2) 139-144
    CrossrefPubMedGoogle Scholar
  • 18 Kikura M, Levy J H, Tanaka K A, Ramsay J G. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.  J Am Coll Surg. 2006;  202 216-222
    CrossrefPubMedGoogle Scholar
  • 19 Zufferey P, Merquiol F, Laporte S et al.. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?.  Anesthesiology. 2006;  105 1034-1046
    CrossrefPubMedGoogle Scholar
  • 20 Levy J H, Adkinson N F. Anaphylaxis during cardiac surgery: implications for clinicans.  Anesth Analg. 2008;  106 392-403
    CrossrefPubMedGoogle Scholar
  • 21 Levy J H, Zaidan J R, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.  Anesth Analg. 1986;  65 739-742
    PubMedGoogle Scholar
  • 22 Levy J H, Schwieger I M, Zaidan J R, Faraj B A, Weintraub W S. Evaluation of patients at risk for protamine reactions.  J Thorac Cardiovasc Surg. 1989;  98 200-204
    PubMedGoogle Scholar
  • 23 Mannucci P M. Treatment of von Willebrand's disease.  N Engl J Med. 2004;  351 683-694
    CrossrefPubMedGoogle Scholar
  • 24 Mannucci P M. Hemostatic drugs.  N Engl J Med. 1998;  339 245-253
    PubMedGoogle Scholar
  • 25 Mannucci P M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.  Blood. 1997;  90 2515-2521
    PubMedGoogle Scholar
  • 26 Federici A B, Mannucci P M. Management of inherited von Willebrand disease in 2007.  Ann Med. 2007;  39 346-358
    CrossrefPubMedGoogle Scholar
  • 27 Frankville D D, Harper G B, Lake C L, Johns R A. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass.  Anesthesiology. 1991;  74 988-996
    CrossrefPubMedGoogle Scholar
  • 28 Rocha E, Llorens R, Paramo J A, Arcas R, Cuesta B, Trenor A M. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?.  Circulation. 1988;  77 1319-1323
    CrossrefPubMedGoogle Scholar
  • 29 Salzman E W, Weinstein M J, Reilly D, Ware J A. Adventures in hemostasis. Desmopressin in cardiac surgery.  Arch Surg. 1993;  128 212-217
    CrossrefPubMedGoogle Scholar
  • 30 Salzman E W, Weinstein M J, Weintraub R M et al.. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial.  N Engl J Med. 1986;  314 1402-1406
    CrossrefPubMedGoogle Scholar
  • 31 Weinstein M, Ware J A, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate.  Blood. 1988;  71 1648-1655
    PubMedGoogle Scholar
  • 32 de Prost D, Barbier-Boehm G, Hazebroucq J et al.. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.  Thromb Haemost. 1992;  68 106-110
    PubMedGoogle Scholar
  • 33 Mannucci P M, Carlsson S, Harris A S. Desmopressin, surgery and thrombosis.  Thromb Haemost. 1994;  71 154-155
    PubMedGoogle Scholar
  • 34 Nielsen V G, Levy J H. Fibrinogen and bleeding: old molecule–new ideas.  Anesth Analg. 2007;  105 902-903
    CrossrefPubMedGoogle Scholar
  • 35 Blome M, Isgro F, Kiessling A H et al.. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery.  Thromb Haemost. 2005;  93 1101-1107
    PubMedGoogle Scholar
  • 36 Charbit B, Mandelbrot L, Samain E et al.. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage.  J Thromb Haemost. 2007;  5 266-273
    CrossrefPubMedGoogle Scholar
  • 37 Steiner M E, Key N S, Levy J H. Activated recombinant factor VII in cardiac surgery.  Curr Opin Anaesthesiol. 2005;  18 89-92
    CrossrefPubMedGoogle Scholar
  • 38 Roberts H R, Monroe D M, White G C. The use of recombinant factor VIIa in the treatment of bleeding disorders.  Blood. 2004;  104 3858-3864
    CrossrefPubMedGoogle Scholar
  • 39 ten Cate H, Bauer K A, Levi M et al.. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.  J Clin Invest. 1993;  92 1207-1212
    CrossrefPubMedGoogle Scholar
  • 40 Butenas S, Brummel K E, Branda R F, Paradis S G, Mann K G. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.  Blood. 2002;  99 923-930
    CrossrefPubMedGoogle Scholar
  • 41 Levy J H, Fingerhut A, Brott T, Langbakke I H, Erhardtsen E, Porte R J. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.  Transfusion. 2006;  46 919-933
    CrossrefPubMedGoogle Scholar
  • 42 O'Connell K A, Wood J J, Wise R P, Lozier J N, Braun M M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.  JAMA. 2006;  295 293-298
    CrossrefPubMedGoogle Scholar
  • 43 Ozgonenel B, O'Malley B, Krishen P, Eisenbrey A B. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital.  Am J Hematol. 2007;  82 1091-1094
    CrossrefPubMedGoogle Scholar
  • 44 Dager W E, King J H, Regalia R C et al.. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.  Pharmacotherapy. 2006;  26 1091-1098
    CrossrefPubMedGoogle Scholar
  • 45 Lankiewicz M W, Hays J, Friedman K D, Tinkoff G, Blatt P M. Urgent reversal of warfarin with prothrombin complex concentrate.  J Thromb Haemost. 2006;  4 967-970
    CrossrefPubMedGoogle Scholar
  • 46 Kessler C M. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?.  J Thromb Haemost. 2006;  4 963-966
    CrossrefPubMedGoogle Scholar
  • 47 Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.  Thromb Res. 2007;  119 643-651
    CrossrefPubMedGoogle Scholar
  • 48 Taketomi T, Szlam F, Levy J H, Tanaka K A. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.  Blood Coagul Fibrinolysis. 2008;  19 106-108
    CrossrefPubMedGoogle Scholar

Jerrold H LevyM.D. F.A.H.A. 

Emory University Hospital, 1364 Clifton Road

NE, Atlanta, GA 30322

Email: jlevy01@emory.edu